MTOR and neoplasm: Recent findings also demonstrate that modulations in T cell anti-tumor immunity contribute to mTOR inhibitor efficacy [4], and reactivation of anti-tumor immunity promotes sustained responses in several other nonimmune-based treatments, including chemotherapy [5,6].